news
Study to support U.S. FDA approval of sacral neuromodulation device in patients with urinary urgency incontinence symptoms SAN JOSE, Calif., Oct. 10, 2022 /PRNewswire/ — Neuspera® Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced the first patient successfully implanted with the Nuvella™ system in its pivotal clinical trial (SANS-UUI). The […]
Hovard brings a wealth of medical device senior leadership experience to the company as it works to advance sacral neuromodulation therapies SAN JOSE, Calif., Sept. 6, 2022 /PRNewswire/ — Neuspera® Medical, a medical device company developing implantable medical device technology for patients with chronic illness, today announced the hiring of seasoned medtech executive, Steffen Hovard as Chief Executive Officer. […]
San Jose, CA – August 4, 2022– Neuspera® Medical, a medical device company developing implantable medical device technology for patients battling chronic illness, today announced the hiring of Steven Siegel, MD, as Chief Medical Officer. Dr. Siegel joined Neuspera as the company recently began enrollment of the second phase of their pivotal clinical trial (SANS-UUI). […]
Pivotal trial to study the safety and efficacy of sacral nerve stimulation in patients with urinary urgency incontinence symptoms SAN JOSE, Calif., June 14, 2022 /PRNewswire/ — Neuspera® Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced it will begin enrollment in its pivotal clinical trial (SANS-UUI), a single-arm study that will […]
Ultra-Miniaturized Device is Smallest-Known Sacral Nerve Implant SAN JOSE, Calif., July 20, 2021 /PRNewswire/ — Neuspera Medical Inc., a clinical stage, private venture capital backed neuromodulation company, today announced the closing of the company’s $65 million series C equity financing. The Series C round was co-led by Vertex Ventures HC and Treo Ventures. Lori Hu, a Managing Director at Vertex Ventures […]
SAN JOSE, Calif., July 20, 2021 /PRNewswire/ — Neuspera Medical Inc., a clinical stage, private venture capital backed neuromodulation company, today announced the closing of the company’s $65 million series C equity financing. The Series C round was co-led by Vertex Ventures HC and Treo Ventures. Lori Hu, a Managing Director at Vertex Ventures HC and Mudit K. Jain, Ph.D. Managing Partner, […]
Regulatory Approval to Start Phase I of its Pivotal Trial SAN JOSE, Calif., Dec. 10, 2019 /PRNewswire/ — Neuspera Medical Inc., a clinical stage, private, venture capital backed neuromodulation company, announced the receipt of an Investigational Device Exemption (IDE) from the FDA – enabling the company to conduct the first long-term clinical trial of its ultra-miniaturized neuromodulation platform. […]
Neuspera Medical has raised a new total of $26 million in equity financing, following the closing of the second tranche of its series B round, to help fund clinical testing programs for its neuromodulation implants. Each of the round’s original investors returned to participate, including 6 Dimensions Capital, Action Potential Venture Capital, Windham Venture Partners, […]
Neuspera leverages exclusively licensed mid-field powering techniques to engineer miniaturized injectable neuromodulation technologies (aka electroceuticals). Neuspera’s implantable module is more than 100 times smaller than other neuromodulation devices and may substantially reduce implant procedure complexity, time, patient complication and post-surgical pain. The idea is that miniature devices can modulate the electrical impulses in the body, […]
Neuspera Medical had been working under the radar for some time on about $1 million in angel financing. Now, it’s raised an $8 million Series A financing after bringing in a high-profile exec to lead its effort. The Santa Clara, CA-based startup is aiming for a futuristic field that already has substantial strategic interest: electroceuticals. […]